/
ACXP
$1.68+$0.16 (+10.53%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$6.5M
4M shares
52-week range
$1.33 – $11.73
3% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
67.59%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-125.92
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $3.5M | $2.2M | $2.0M | $4.8M | $6.0M | $5.4M | $1.83B |
| Operating income | −$5.9M | −$4.6M | −$12.8M | −$12.1M | −$14.6M | −$14.1M | −$8.1M |
| EBITDA | $0 | $0 | −$12.7M | −$12.1M | −$14.6M | $0 | −$8.0M |
| Net income | −$5.9M | −$4.6M | −$12.7M | −$12.1M | −$14.6M | −$14.1M | −$8.0M |
| Net margin | — | — | — | — | — | — | — |
| EPS (diluted) | -12.00 | -9.28 | -24.96 | -22.36 | -23.01 | -17.59 | -5.32 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $276000 | $-1.65 | $-1.65–$-1.65 | 1 |
| 2027 | $4M | $-1.77 | $-1.77–$-1.77 | 1 |
| 2028 | $25M | $-2.02 | $-2.02–$-2.02 | 1 |
| 2029 | $47M | $-1.76 | $-1.76–$-1.76 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$5040.79
Price
$1.68
Implied upside
+299947%
Peer comparison
Acurx Pharmaceuticals, Inc. Common Stock
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
www.acurxpharma.com- Employees
- 4
- IPO / List date
- Jun 25, 2021
- HQ
- STATEN ISLAND, NY
Held by traders on TradeandTell
No one on the platform currently holds ACXP.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in ACXP as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-08-05 | 1-for-20reverse |
Recent trades on TradeandTell
No one on the platform has traded ACXP yet.
